Involvement of αvβ5 integrin in the establishment of autocrine TGF-β signaling in dermal fibroblasts derived from localized scleroderma

Journal of Investigative Dermatology

Volumn 126, Issue 8, 2006, Pages 1761-1769

  Asano, Yoshihide ^a   Ihn, Hironobu ^a,b   Jinnin, Masatoshi ^a   Mimura, Yoshihiro ^a   Tamaki, Kunihiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANTISENSE OLIGONUCLEOTIDE; COLLAGEN TYPE 1; DNA; INTEGRIN; INTEGRIN ALPHAVBETA5 ANTIBODY; INTERSTITIAL COLLAGENASE; LUCIFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN; PROTEIN ANTIBODY; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ANTIBODY; DNA BINDING PROTEIN; MEMBRANE PROTEIN; SMAD3 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; VITRONECTIN RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; CELL STIMULATION; COCULTURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMIS; ENZYME ACTIVITY; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; LATENT PERIOD; LOCALIZED SCLERODERMA; MOLECULAR STABILITY; MYOFIBROBLAST; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SUBCUTANEOUS TISSUE; SYSTEMIC SCLEROSIS; UPREGULATION; BIOPSY; CELL CULTURE; DRUG ANTAGONISM; FEMALE; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; MALE; METABOLISM; PATHOLOGY;

ANTIBODIES; AUTOCRINE COMMUNICATION; BIOPSY; CELLS, CULTURED; COLLAGEN TYPE I; DERMIS; DNA-BINDING PROTEINS; FEMALE; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTEGRINS; MALE; MATRIX METALLOPROTEINASE 1; MEMBRANE PROTEINS; RECEPTORS, VITRONECTIN; SCLERODERMA, LOCALIZED; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33746141265     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700331     Document Type: Article

References (40)

1. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB (1994) An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 216:276-84
2. Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGF-β activation. J Cell Sci 116:217-24
3. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K (2004a) Phosphatidylinositol 3-kinase is involved in α2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol 172:7123-35
4. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K (2004b) Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 113:253-64
5. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K (2004c) Increased expression levels of integrin αvβ5 on scleroderma fibroblasts. Am J Pathol 164:1275-92
6. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K (2005a) Differential effects of the immunosuppressant FK-506 on human α2(I) collagen gene expression and transforming growth factor β signaling in normal and scleroderma fibroblasts. Arthritis Rheum 52:1237-47
7. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K (2005b) Involvement of αvβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signaling in systemic sclerosis fibroblasts. Arthritis Rheum 52:2897-905
8. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K (2005c) Increased expression of integrin αvβ3 contributes to the establishment of autocrine TGF-β signaling in scleroderma fibroblasts. J Immunol 175:7708-18
9. Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K (2006) Increased expression of integrin αvβ5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 168:499-510
10. Buckingham RB, Prince RK, Rodnan GP, Taylor F (1978) Increased collagen accumulation in dermal fibroblast cultures from patients with progressive systemic sclerosis (scleroderma). J Lab Clin Med 92:5-21
11. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SH, Lawler J, Hynes RO et al. (1998) Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93:1159-70
12. Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I et al. (2003) Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice. J Biol Chem 278:25109-19
13. Falanga V, Tiegs SL, Alstadt SP, Roberts AB, Sporn MB (1987) Transforming growth factor-β: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. J Invest Dermatol 89:100-4
14. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C (1994) Immunocytochemical localization and serologic detection of transforming growth factor β1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 37:278-88
15. Huang X, Griffiths M, Wu J, Farese RV Jr, Sheppard D (2000) Normal development, wound healing, and adenovirus susceptibility in β5-deficient mice. Mol Cell Biol 20:755-9
16. Ihn H, Yamane K, Kubo M, Tamaki K (2001) Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 44:474-80
17. Jablonska S, Rodnan GP (1979) Localized forms of scleroderma. Clin Rheum Dis 5:215-41
18. Jelaska A, Arakawa M, Broketa G, Korn JH (1996) Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts: increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 39:1338-46
19. Kahaleh B (1993) Immunologic aspects of scleroderma. Curr Opin Rheumatol 5:760-5
20. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M (1998) Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 110:47-51
21. Kubo M, Ihn H, Yamane K, Tamaki K (2001) Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 44:731-4
22. LeRoy EC (1974) Increased collagen synthesis by SSc skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54:880-9
23. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM (1989) A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor β the answer? Arthritis Rheum 32:817-25
24. Ludbrook SB, Barry ST, Delves CJ, Horgan CMT (2003) The integrin αvβ3 is a receptor for the latency-associated peptides of transforming growth factors β1 and β3. Biochem J 369:311-8
25. Lyons RM, Gentry LE, Purchio AF, Moses HL (1990) Mechanism of activation of latent recombinant transforming growth factor-β1 by plasmin. J Cell Biol 110:1361-7
26. Massague J (1990) Transforming growth factor-β family. Ann Rev Cell Biol 6:597-641
27. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H et al. (2002) The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J Cell Biol 157:493-507
28. Munger JS, Harpel JG, Giancotti FG, Rifkin DB (1998) Interactions between growth factors and integrins: latent forms of transforming growth factor-β are ligands for the integrin αvβ1. Mol Biol Cell 9:2627-38
29. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J et al. (1999) The integrin αvβ6 binds and activates latent TGF-β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319-28
30. Peltonen J, Kahari L, Uitto J, Jimenez SA (1990) Increased expression of type VI collagen genes in systemic sclerosis. Arthritis Rheum 33:1829-35
31. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH (1987) Transforming growth factor-β increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 79:1285-8
32. Rudnicka L, Varga J, Christiano AM, Iozzo RV, Jimenez SA, Uitto J (1994) Elevated expression of type VII collagen in the skin of patients with systemic sclerosis. Regulation by transforming growth factor β. J Clin Invest 93:1709-15
33. Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K (1994) Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 31:567-71
34. Schultz-Cherry S, Lawler J, Murphy-Ullrich JE (1994) The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-β. J Biol Chem 269:26783-8
35. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M et al. (1992) Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359:693-9
36. Takehara K, Sato S (2005) Localized scleroderma is an autoimmune disorder. Rheumatology 44:274-9
37. Wahl SM (1994) Transforming growth factor β: the good, the bad, and the ugly. J Exp Med 180:1587-90
38. Xu WD, LeRoy EC, Smith EA (1991) Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-β. J Rheumatol 18:241-6
39. Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K et al. (2002) c-myc is a downstream target of the Smad pathway. J Biol Chem 277:854-61
40. Ylänne J (1998) Conserved functions of the cytoplasmic domains of integrin β subunits. Front Biosci 3:877-86